Meeting
2024 ASCO Breakthrough
Neoadjuvant treatment with trastuzumab and pertuzumab plus fulvestrant in older patients with HER2-positive, ER-positive early breast cancer.
Authors
Juan Jose Celis
Sociedad Anticancerosa de Venezuela, Caracas, Venezuela (Bolivarian Republic of)
Juan Jose Celis , Vanessa Rodriguez , Crismar Rodriguez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Local Disease
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 13)
DOI
10.1200/JCO.2024.42.23_suppl.13
Abstract #
13
Poster Bd #
B2
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.
First Author: Giampaolo Bianchini
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
First Author: Nicholas Patrick McAndrew
Poster
2022 ASCO Annual Meeting
Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.
First Author: Alexandra Thomas